Streetbeat News

KRRO

Korro Bio, Inc.

https://www.korrobio.com

Industry

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Open

49.70

Mkt cap

446M

Volume

92K

High

49.90

P/E Ratio

-5.73

52-wk high

98.00

Low

46.19

Div yield

N/A

52-wk low

30.00

Korro Bio, Inc. (Nasdaq: KRRO) will present at the Jefferies London Healthcare Conference on November 19, 2024. The presentation will be led by CEO Ram Aiyar, with participation from CFO Vineet Agarwal and CMO Kemi Olugemo.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Korro Bio (NASDAQ:KRRO) and raised the price target from $95 to $105.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:31 pm

Raymond James has initiated coverage on Korro Bio with a Strong Buy rating and set a price target of $153.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:22 pm

HC Wainwright & Co. has maintained a Buy rating on Korro Bio and increased the price target from $100 to $115, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 11:00 am

The article highlights significant intraday movements in healthcare stocks, with notable gainers including 180 Life Sciences, Korro Bio, and Universe Pharmaceuticals, and losers such as Novavax and Tevogen Bio Holdings.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

United Airlines reported better-than-expected earnings, leading to a 9.3% stock increase. Other stocks like Korro Bio, Wave Life Sciences, and Morgan Stanley also saw significant gains due to positive developments.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 2:23 pm

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Korro Bio (NASDAQ:KRRO) and maintained a price target of $95.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:09 pm

Novo Nordisk has entered a $600 million partnership with NanoVation Therapeutics to develop genetic medicines targeting cardiometabolic and rare diseases. The collaboration will utilize NanoVation's lipid nanoparticle technology. Novo Nordisk also announced a collaboration with Korro Bio for RNA editing therapies.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 7:30 pm

U.S. stocks mostly rose with the Nasdaq Composite gaining 0.2%. Energy shares increased by 1.3%, while healthcare shares fell by 1.1%. Notable stock movements included BurgerFi International's 88% rise, Galmed Pharmaceuticals' 422% surge, and Compass Minerals' 24% gain. Tupperware Brands dropped 58% amid bankruptcy concerns.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 6:31 pm

U.S. stocks rose with the Dow Jones, NASDAQ, and S&P 500 all gaining. Notable stock movements included BurgerFi International's 96% surge after securing financing, Galmed Pharmaceuticals' 99% jump after regaining Nasdaq compliance, and Compass Minerals' 28% rise on strong revenue forecasts. Tupperware Brands fell 58% amid bankruptcy concerns, while Netcapital and Korro Bio also saw declines.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 4:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.